56 related articles for article (PubMed ID: 36097899)
1. [The value of immunohistochemical expression of Ki-67 and CD34 in differentiating ductal carcinoma in situ from ductal carcinoma in situ-like invasive breast cancer].
Pan XY; Wu JK; Lang ZQ; Qu L; Jiang L
Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):838-842. PubMed ID: 36097899
[No Abstract] [Full Text] [Related]
2. Genetic predisposition to ductal carcinoma in situ of the breast.
Petridis C; Brook MN; Shah V; Kohut K; Gorman P; Caneppele M; Levi D; Papouli E; Orr N; Cox A; Cross SS; Dos-Santos-Silva I; Peto J; Swerdlow A; Schoemaker MJ; Bolla MK; Wang Q; Dennis J; Michailidou K; Benitez J; González-Neira A; Tessier DC; Vincent D; Li J; Figueroa J; Kristensen V; Borresen-Dale AL; Soucy P; Simard J; Milne RL; Giles GG; Margolin S; Lindblom A; Brüning T; Brauch H; Southey MC; Hopper JL; Dörk T; Bogdanova NV; Kabisch M; Hamann U; Schmutzler RK; Meindl A; Brenner H; Arndt V; Winqvist R; Pylkäs K; Fasching PA; Beckmann MW; Lubinski J; Jakubowska A; Mulligan AM; Andrulis IL; Tollenaar RA; Devilee P; Le Marchand L; Haiman CA; Mannermaa A; Kosma VM; Radice P; Peterlongo P; Marme F; Burwinkel B; van Deurzen CH; Hollestelle A; Miller N; Kerin MJ; Lambrechts D; Floris G; Wesseling J; Flyger H; Bojesen SE; Yao S; Ambrosone CB; Chenevix-Trench G; Truong T; Guénel P; Rudolph A; Chang-Claude J; Nevanlinna H; Blomqvist C; Czene K; Brand JS; Olson JE; Couch FJ; Dunning AM; Hall P; Easton DF; Pharoah PD; Pinder SE; Schmidt MK; Tomlinson I; Roylance R; García-Closas M; Sawyer EJ
Breast Cancer Res; 2016 Feb; 18(1):22. PubMed ID: 26884359
[TBL] [Abstract][Full Text] [Related]
3. Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
Zheng ZY; Elsarraj H; Lei JT; Hong Y; Anurag M; Feng L; Kennedy H; Shen Y; Lo F; Zhao Z; Zhang B; Zhang XH; Tawfik OW; Behbod F; Chang EC
Breast Cancer Res; 2022 Oct; 24(1):68. PubMed ID: 36258226
[TBL] [Abstract][Full Text] [Related]
4. Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.
Han X; Liu Y; Zhang S; Li L; Zheng L; Qiu L; Chen J; Zhan Z; Wang S; Ma J; Kang D; Chen J
Int J Cancer; 2024 May; 154(10):1802-1813. PubMed ID: 38268429
[TBL] [Abstract][Full Text] [Related]
5. Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.
Hophan SL; Odnokoz O; Liu H; Luo Y; Khan S; Gradishar W; Zhou Z; Badve S; Torres MA; Wan Y
Endocrinology; 2022 Apr; 163(4):. PubMed ID: 35245349
[TBL] [Abstract][Full Text] [Related]
6. Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.
DeCensi A; Puntoni M; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Lazzeroni M; Vingiani A; Gentilini O; Petrera M; Viale G; Cuzick J; Bonanni B; Pruneri G
Cancer Prev Res (Phila); 2015 Oct; 8(10):888-94. PubMed ID: 26276754
[TBL] [Abstract][Full Text] [Related]
7. Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control study.
Rask G; Wadsten C; Acs B; Hartman J; Fredriksson I; Garmo H; Wärnberg F; Sund M
Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38395442
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of TPL2 may be a predictor of good prognosis in patients with breast invasive ductal carcinoma.
Yu Q; Wan D; Fu R; Li F; Zhang Y
Sci Rep; 2023 Oct; 13(1):17346. PubMed ID: 37833434
[TBL] [Abstract][Full Text] [Related]
9.
Zhang Z; Wang H; Jin Y; Zhou J; Chu C; Tang F; Zou L; Zou Q
Biomark Med; 2023 Jun; 17(12):553-562. PubMed ID: 37814985
[No Abstract] [Full Text] [Related]
10. Study of the Immunohistochemical Expression of p63 in Benign Lesions and Carcinoma of the Breast at a Tertiary Hospital in South India.
Prabhu SD; Rai HS; Nayak R; Naik R; Jayasheelan S
Cureus; 2023 Nov; 15(11):e48557. PubMed ID: 38024052
[TBL] [Abstract][Full Text] [Related]
11. Cytomorphological Assessment in Aspirates of Ductal Carcinoma in situ: Correlations with Histopathologic Grade, Architectural Pattern, and Invasion.
Li JJX; Chow MBCY; Ng JKM; Tsang JY; Tse GM
Acta Cytol; 2024; 68(1):45-53. PubMed ID: 38128502
[TBL] [Abstract][Full Text] [Related]
12. Loss of myoepithelial calponin-1 characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition.
Mitchell E; Jindal S; Chan T; Narasimhan J; Sivagnanam S; Gray E; Chang YH; Weinmann S; Schedin P
Mol Carcinog; 2020 Jul; 59(7):701-712. PubMed ID: 32134153
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study.
Peila R; Rohan TE
Int J Cancer; 2024 Apr; 154(7):1191-1203. PubMed ID: 38013398
[TBL] [Abstract][Full Text] [Related]
14. A Preliminary Analysis of Ki-67 Expression in Breast Cancer in the Caribbean.
Jogie JA; Maharaj A; Mahase T; Bhagwandeen S; Ramcharan L; Mohammed R; Ramdass J; Deyalsingh V
Cureus; 2023 Apr; 15(4):e38351. PubMed ID: 37266061
[TBL] [Abstract][Full Text] [Related]
15. Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast.
Teo NB; Shoker BS; Jarvis C; Sloane JP; Holcombe C
J Clin Pathol; 2003 Dec; 56(12):919-23. PubMed ID: 14645350
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological characteristics and immune microenvironment of breast squamous cell carcinoma].
Liang JY; Wang YM; Wen Z; Zhang WH; Gao ZZ; Wang Z; Guo SP
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):337-343. PubMed ID: 38556816
[No Abstract] [Full Text] [Related]
17. Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory- and pathologist-specific feedback reports.
van Dooijeweert C; van Diest PJ; Baas IO; van der Wall E; Deckers IAG
Diagn Pathol; 2020 May; 15(1):52. PubMed ID: 32393303
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Staining Characteristics of Low-Grade Invasive Ductal Carcinoma Using the ADH5 Cocktail (CK5/14, P63, and CK7/18): A Potential Interpretative Pitfall.
Al-Refai R; Bendari A; Morrar D; Sham S; Kataw L; Garajayev A; Hajiyeva S
Diagnostics (Basel); 2023 Sep; 13(18):. PubMed ID: 37761331
[No Abstract] [Full Text] [Related]
19. Low grade Ductal Carcinoma in situ (DCIS): how best to describe it?
Fallowfield L; Matthews L; Francis A; Jenkins V; Rea D
Breast; 2014 Oct; 23(5):693-6. PubMed ID: 24986765
[TBL] [Abstract][Full Text] [Related]
20. A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression.
Norton KA; Wininger M; Bhanot G; Ganesan S; Barnard N; Shinbrot T
J Theor Biol; 2010 Apr; 263(4):393-406. PubMed ID: 20006623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
